The identification of SLITRK4 as a driver of CRC liver metastasis through the PI3K/AKT/NFκB pathway highlights its potential as a therapeutic target, emphasizing the need for further investigation into its role in tumor progression and immune modulation. This evidence concerns the gene PIK3CD and neoplasm.